ASCO 2006 Exemestane: Una Nuova Realtà per la Terapia Adiuvante Del Carcinoma Mammario

Smith I.E. , Dowsett M. : Aromatase inhibitors in breast cancer. N Engl J Med, 348: 2431–2442, 2003.

Kaufmann M. , Bajetta E. , Dirix L.Y. , Fein L.E. , Jones S.E. , Zilembo N. , Dugardyn J.L. , Nasurdi C. , Mennel R.G. , Cervek J. , Fowst C. , Polli A. , di Salle E. , Arkhipov A. , Piscitelli G. , Miller L.L. , Massimini G for the Exemestane Study Group: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol, 18: 1399–1411, 2000.

Paridaens R. , Dirix L. , Lohrisch C. , Beex L. , Nooij M. , Cameron D. , Biganzoli L. , Cufer T. , Duchateau L. , Hamilton A. , Lobelle J.P. , Piccart M. on behalf of the European Organization for the Research and Treatment of Cancer (EORTC) - Investigational Drug Branch for Breast Cancer (IDBBC): Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol, 14: 1391–1398, 2003.

Paridaens R. , Therasse P. , Dirix L. , Beex L. , Piccart M. , Cameron D. , Cufer T. , Roozendaal K. , Nooij M. , Mattiacci M.R. : First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts). A randomized phase III trial of the EORTC Breast Group. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 515.

Coombes R.C. , Hall E. , Gibson L.J. , Paridaens R. , Jassem J. , Delozier T. , Jones S.E. , Alvarez I. , Bertelli G. , Ortmann O. , Coates A.S. , Bajetta E. , Dodwell D. , Coleman R.E. , Fallowfield L.J. , Mickiewicz E. , Andersen J. , Lonning P.E. , Cocconi G. , Stewart A. , Stuart N. , Snowdon C.F. , Carpentieri M. , Massimini G. , Bliss J.M. for the Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 350: 1081–1092, 2004.

Coombes R.C. , Paridaens R. , Jassem J. , Van de Velde C.J. , Delozier T. , Jones S.E. , Hall E. , Kilburn L.S. , Snowdon C.F. , Bliss J.M. for the Intergroup Exemestane Study (IES): First mature analysis of the Intergroup Exemestane Study. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, Part I, Vol 24, No. 18S (June 20 Supplement): LBA527, 2006.

Dowsett M. , Cuzick J. , Wale C. , Howell T. , Houghton J. , Baum M. : Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol, 23: 7512–7517, 2005.

Fallowfield L.J. , Bliss J.M. , Porter L.S. , Price M.H. , Snowdon C.F. , Jones S.E. , Coombes R.C. , Hall E. : Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol, 24: 910–917, 2006.

Fallowfield L. , Cella D. , Cuzick J. , Francis S. , Locker G. , Howell A. : Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol, 22: 4261–4271, 2004.

Howell A. , Cuzick J. , Baum M. , Buzdar A. , Dowsett M. , Forbes J.F. , Hoctin-Boes G. , Houghton J. , Locker G.Y. , Tobias J.S. , ATAC Trialists’ Group: Results of the AT-AC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 365: 60–62, 2005.

Thurlimann B. , Keshaviah A. , Coates A.S. , Mouridsen H. , Mauriac L. , Forbes J.F. , Paridaens R. , Castiglione-Gertsch M. , Gelber R.D. , Rabaglio M. , Smith I. , Wardley A. , Price K.N. , Goldhirsch A. , Breast International Group (BIG) 1–98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 353: 2747–2757, 2005.

Goss P.E. , Ingle J.N. , Martino S. , Robert N.J. , Muss H.B. , Piccart M.J. , Castiglione M. , Tu D. , Shepherd L.E. , Pritchard K.I. , Livingston R.B. , Davidson N.E. , Norton L. , Perez E.A. , Abrams J.S. , Cameron D.A. , Palmer M.J. , Pater J.L. : Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 97: 1262–1271, 2005.

Carlomagno C. , Perrone F. , Gallo C. , De Laurentiis M. , Lauria R. , Morabito A. , Pettinato G. , Panico L. , D'Antonio A. , Bianco A.R. , De Placido S. : c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14: 2702–2708, 1996.

Piccart-Gebhart M.J. , Procter M. , Leyland-Jones B. , Goldhirsch A. , Untch M. , Smith I. , Gianni L. , Baselga J. , Bell R. , Jackisch C. , Cameron D. , Dowsett M. , Barrios C.H. , Steger G. , Huang C.S. , Andersson M. , Inbar M. , Lichinitser M. , Lang I. , Nitz U. , Iwata H. , Thomssen C. , Lohrisch C. , Suter T.M. , Ruschoff J. , Suto T. , Greatorex V. , Ward C. , Straehle C. , McFadden E. , Dolci M.S. , Gelber R.D. , Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659–1672, 2005.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365: 1687–1717, 2005.

Normanno N. , Di Maio M. , De Maio E. , De Luca A. , de Matteis A. , Giordano A. , Perrone F. : NCI-Naple Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer, 12: 721–747, 2005.